FDA approves Novartis' Alzheimer's patch

Novartis has won FDA approval to market its once daily skin patch Exelon for mild to moderate Alzheimer's. The patch is designed to give a continuous dosage of Exelon that delivers the same efficacy rate as the highest dose of the drug in capsule form. It's also supposed to help patients avoid some of the side effects of the capsule while improving memory and everyday performance.

- check out the release on the patch
- here's the AFX report

Related Articles:
New studies support use of Exelon patch. Report
FDA OKs Novartis' Exelon for dementia. Report
Big pharma sees big payback for Alzheimer's research. Report
Alzheimer's patch used to deliver vaccine to mice. Report